NATR

Business Context and Reporting Period

Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2004
Business Overview: The Company manufactures and distributes health and wellness products through a network of independent distributors and managers. Operations are divided into five segments: United States, Latin America, Asia Pacific, Other International, and Synergy Worldwide.

Key Financial Metrics

Note: Financial data is presented in thousands. The Company reclassified volume incentive rebates as a reduction of sales revenue rather than an expense, which affects revenue and expense totals but not operating income.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 25.2% for the quarter and 23.9% for the six-month period compared to the prior year. This growth was driven primarily by the Synergy Worldwide segment (up from $1.8M to $18.8M in Q2) and international operations.
• Profitability Surge: Net income for the quarter increased 328.6% to $4.8 million, and for the six months increased 186.2% to $7.8 million. This was aided by a $2.2 million income tax benefit recognized in Q2 following a foreign tax asset study.
• Segment Performance:
  • United States: Sales declined 6.4% in Q2, largely due to a 94% devaluation of the Dominican Republic peso.
  • Asia Pacific: Sales declined 35.6% in Q2 due to increased competition in South Korea.
  • Latin America & Other: Both regions showed significant growth (5.2% and 27.8% respectively in Q2).
• Expense Trends: Volume incentives as a percentage of sales increased to 37.9% (Q2) due to the higher mix of Synergy Worldwide sales, which carry higher commission rates. SG&A expenses increased due to the expansion of Synergy Worldwide.

Guidance, Outlook, and Risks

• Outlook: Management expects Cost of Goods Sold (COGS) to decrease slightly as a percentage of sales for the remainder of 2004 due to a price increase in the U.S. market (effective April 1, 2004) and continued Synergy growth. SG&A as a percentage of sales is expected to decrease due to cost controls and revenue growth.
• Liquidity: The Company maintains a $15 million line of credit with no outstanding borrowings as of June 30, 2004. The maturity date was extended to July 1, 2006. Management believes working capital needs can be met through cash, operations, and the credit line.
• Risks and Contingencies:
  • Product Liability: The Company self-insures for product liability. While it complied with the FDA ban on ephedra in April 2004, it faces inherent risks regarding claims for ingested products. No assurance can be given that current accruals are sufficient.
  • Foreign Currency: Approximately 55% of revenue is realized outside the U.S. A strengthening U.S. dollar negatively impacts operating results. The Company does not use derivative instruments for hedging.
  • Market Risk: Investments totaling $11.2 million are subject to interest rate and market risk, though a 1% change in rates is not expected to be material.

Investor Verification Checklist

• Revenue Reclassification: Verify the impact of the EITF 01-9 reclassification (rebates treated as revenue reduction) on year-over-year comparisons of gross margin and expense ratios.
• Tax Benefit Sustainability: Confirm whether the $2.2 million tax benefit recognized in Q2 is a one-time event or indicative of future tax rates, as management noted the current rate is not indicative of the full year.
• Synergy Worldwide Growth: Assess the sustainability of the rapid growth in the Synergy Worldwide segment, which drove the majority of revenue and profit increases.
• Product Liability Exposure: Review the adequacy of self-insurance accruals given the regulatory scrutiny on ingredients like ephedra and kava.
• Foreign Currency Impact: Monitor exchange rate fluctuations, particularly in the Dominican Republic and other key international markets, given the lack of hedging strategies.